BACKGROUND: Earlier detection and diagnosis of head and neck squamous cell carcinoma (HNSCC) should lead to improved outcomes. However, to the authors' knowledge, no effective screening strategy has been identified to date. In the current study, the authors evaluated whether it would be useful to screen subjects targeted for lung cancer screening for HNSCC as well. METHODS: Medical records, death certificates, and cancer registry and questionnaire data were used to determine the number of observed incident HNSCC cases in the Pittsburgh Lung Screening Study (PLuSS), a cohort of current and former smokers aged ≥50 years with a ≥12.5 pack-year smoking history. The expected number of cases was estimated using stratum-specific incidence rates obtained from Surveillance, Epidemiology, and End Results data for 2000 through 2011. The standardized incidence ratio was calculated to examine the difference between the observed and expected number of cases. RESULTS: Of the 3587 at-risk participants in the PLuSS, 23 (0.64%) developed HNSCC over a total of 32,201 person-years of follow-up. This finding was significantly higher than expected based on incidence rates obtained from the Surveillance, Epidemiology, and End Results program (13.70 cases expected; standardized incidence ratio, 1.68 [95% confidence interval, 1.06-2.52]). The excess burden of HNSCC in the PLuSS was 28.9 cases per 100,000 person-years. Observed incident cases were significantly more often male, had started smoking at a younger age, smoked more per day, and had more pack-years of smoking than the rest of the PLuSS at-risk participants. CONCLUSIONS: The results of the current study provide a rationale for offering head and neck cancer screening along with computed tomography screening for lung cancer. Randomized controlled trials that assess the effectiveness of adding examination of the head and neck area to lung cancer screening programs are warranted.
BACKGROUND: Earlier detection and diagnosis of head and neck squamous cell carcinoma (HNSCC) should lead to improved outcomes. However, to the authors' knowledge, no effective screening strategy has been identified to date. In the current study, the authors evaluated whether it would be useful to screen subjects targeted for lung cancer screening for HNSCC as well. METHODS: Medical records, death certificates, and cancer registry and questionnaire data were used to determine the number of observed incident HNSCC cases in the Pittsburgh Lung Screening Study (PLuSS), a cohort of current and former smokers aged ≥50 years with a ≥12.5 pack-year smoking history. The expected number of cases was estimated using stratum-specific incidence rates obtained from Surveillance, Epidemiology, and End Results data for 2000 through 2011. The standardized incidence ratio was calculated to examine the difference between the observed and expected number of cases. RESULTS: Of the 3587 at-risk participants in the PLuSS, 23 (0.64%) developed HNSCC over a total of 32,201 person-years of follow-up. This finding was significantly higher than expected based on incidence rates obtained from the Surveillance, Epidemiology, and End Results program (13.70 cases expected; standardized incidence ratio, 1.68 [95% confidence interval, 1.06-2.52]). The excess burden of HNSCC in the PLuSS was 28.9 cases per 100,000 person-years. Observed incident cases were significantly more often male, had started smoking at a younger age, smoked more per day, and had more pack-years of smoking than the rest of the PLuSS at-risk participants. CONCLUSIONS: The results of the current study provide a rationale for offering head and neck cancer screening along with computed tomography screening for lung cancer. Randomized controlled trials that assess the effectiveness of adding examination of the head and neck area to lung cancer screening programs are warranted.
Authors: Andrew G Shuman; Payam Entezami; Anna S Chernin; Nancy E Wallace; Jeremy M G Taylor; Norman D Hogikyan Journal: Otolaryngol Head Neck Surg Date: 2010-09 Impact factor: 3.497
Authors: David O Wilson; Joel L Weissfeld; Arzu Balkan; Jeffrey G Schragin; Carl R Fuhrman; Stephen N Fisher; Jonathan Wilson; Joseph K Leader; Jill M Siegfried; Steven D Shapiro; Frank C Sciurba Journal: Am J Respir Crit Care Med Date: 2008-06-19 Impact factor: 21.405
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: David O Wilson; Joel L Weissfeld; Carl R Fuhrman; Stephen N Fisher; Paula Balogh; Rodney J Landreneau; James D Luketich; Jill M Siegfried Journal: Am J Respir Crit Care Med Date: 2008-07-17 Impact factor: 21.405
Authors: Mia Hashibe; Paul Brennan; Shu-Chun Chuang; Stefania Boccia; Xavier Castellsague; Chu Chen; Maria Paula Curado; Luigino Dal Maso; Alexander W Daudt; Eleonora Fabianova; Leticia Fernandez; Victor Wünsch-Filho; Silvia Franceschi; Richard B Hayes; Rolando Herrero; Karl Kelsey; Sergio Koifman; Carlo La Vecchia; Philip Lazarus; Fabio Levi; Juan J Lence; Dana Mates; Elena Matos; Ana Menezes; Michael D McClean; Joshua Muscat; Jose Eluf-Neto; Andrew F Olshan; Mark Purdue; Peter Rudnai; Stephen M Schwartz; Elaine Smith; Erich M Sturgis; Neonilia Szeszenia-Dabrowska; Renato Talamini; Qingyi Wei; Deborah M Winn; Oxana Shangina; Agnieszka Pilarska; Zuo-Feng Zhang; Gilles Ferro; Julien Berthiller; Paolo Boffetta Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-03 Impact factor: 4.254
Authors: A C H Willemsen; J H R J Degens; L W J Baijens; A-M C Dingemans; A Hoeben; F J P Hoebers; D K M De Ruysscher; A M W J Schols Journal: Front Nutr Date: 2020-11-26